The Central Social Insurance Medical Council, better known as Chuikyo, appears to see the need to set up new dosage…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY PMDA’s Regulatory Consultation Service Off to Good Start, but More Effort Needed to Promote Face-to-Face Advisory Meetings: Dr Isobe
August 22, 2012
-
BUSINESS Mediscience Stepping Up Athlete Recruitments as CMRs
August 21, 2012
-
REGULATORY Healthcare to Receive Priority in FY2013 Draft Budget Request Guidelines
August 21, 2012
-
BUSINESS DSP to Set Up Cancer Institute Led by CEO of Its US Subsidiary BBI
August 21, 2012
-
REGULATORY PAFSC’s 1st Committee to Review 7 Products Including Bayer Yakuhin’s AMD Drug on Aug. 31
August 20, 2012
-
BUSINESS “Sense of Achievement” Motivates MRs; Brach Managers to Be Blamed for Miscommunications: Survey of Managers
August 20, 2012
-
REGULATORY US Regulation Could Delay Introduction of PBRER as ICH Standard
August 17, 2012
-
REGULATORY MHLW Approves Allegra Generics of 3 Companies for Listing in December
August 16, 2012
-
BUSINESS Differences in Concurrent-Use Indications for DPP-4 Inhibitors to Be Eliminated through Special Clinical Trials
August 15, 2012
-
REGULATORY Neo-Morgan Laboratory Developing a Variety of Organisms Using “Disparity Mutagenesis Technology”
August 14, 2012
-
BUSINESS Business Strategies of Generics Manufacturers Become Evident Ahead of Upcoming Round of Patent Expiries
August 13, 2012
-
REGULATORY MHLW to Include Generic Drug Share Targets in Next 5-Year Medical Spending Optimization Plans in Response to Requests by Insurers
August 10, 2012
-
ORGANIZATION PI Forum to Make Proposals to Promote R&D, Make Pharmaceuticals Japan’s Key Industry: Chairman Toyoda
August 9, 2012
-
BUSINESS Daiichi Sankyo to Strengthen Cardiovascular Field by Comarketing Diabetes Treatments, Focusing on SGLT-2 Inhibitor
August 8, 2012
-
REGULATORY MOF Wants Generic Drug Share to Reach European, US Levels: Budget Examiner Shinkawa
August 8, 2012
-
BUSINESS 6 Listed Wholesalers Post Low Price Settlement Rates as of End-June, Showing Declines Compared to 2 Years Earlier
August 7, 2012
-
BUSINESS Astellas to “Seek Every Opportunity” for Domestic Vaccine Business, Including Alliances with Foreign Companies
August 6, 2012
-
BUSINESS DSP to Establish Sales Force for Anticancer Drugs in North America
August 3, 2012
-
BUSINESS Daiichi Sankyo: April-June Nexium Sales 6% of Full-Year Target, Set to Boost Promotion after Lifting of Long-Term Prescription Ban
August 2, 2012
-
REGULATORY Council Approves Economic Revitalization Strategy with Priority on 3 Sectors Including Life Science
August 1, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…